Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DT-061 is an orally bioavailable protein phosphatase 2A (PP2A) activator. It could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,230.00 | |
50 mg | 8-10 weeks | $ 1,610.00 | |
100 mg | 8-10 weeks | $ 2,440.00 |
Description | DT-061 is an orally bioavailable protein phosphatase 2A (PP2A) activator. It could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis. |
In vivo | DT-061 combined with AZD6244 is more significantly efficient. DT-061 (5 mg/kg, oral gavage, 4 weeks) displays single-agent activity in inhibiting H358 or H441 xenograft growth. |
Molecular Weight | 520.52 |
Formula | C25H23F3N2O5S |
CAS No. | 1809427-19-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (240.14 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DT-061 1809427-19-7 Metabolism Phosphatase DT061 DT 061 inhibitor inhibit